Zoetis, an animal health company, completed the acquisition of adivo, a research company in the field of advanced biopharmaceuticals for veterinary medicine. Financial terms were undisclosed. Through the transaction, Zoetis expands its competencies in the field of biologics, i.e., biotechnologically developed agents. Following their broad success in human medicine, therapeutic antibodies are increasingly gaining importance in veterinary medicine as well. The acquisition of adivo provides Zoetis with access to technological know-how as well as to existing species-specific antibody libraries and opens up the possibility for Zoetis to develop numerous novel veterinary products.